An Open Label, Multi-Centre, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients with Non-Transfusion Dependent Thalassaemia (THETIS)

Trial Profile

An Open Label, Multi-Centre, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients with Non-Transfusion Dependent Thalassaemia (THETIS)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Iron overload
  • Focus Therapeutic Use
  • Acronyms THETIS
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 30 Mar 2015 According to a Novartis media release, US FDA has approved deferasirox [Jadenu] tablets for oral suspension for the treatment of chronic iron overload in non-transfusion-dependent thalassemia syndrome patients of age 10 years and older.
    • 20 Feb 2014 Status has gone changed to active, no longer recruiting, according to United Kingdom Clinical Research Network record.
    • 25 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top